Beta Bionics, Inc. (BBNX) Stock Statistics & Valuation Metrics

Beta Bionics, Inc. has a market cap or net worth of $1.17B. The enterprise value is $523.95.

Beta Bionics, Inc. has 53,946,213 shares outstanding. The number of shares has decreased by -2.65% in one year.

Beta Bionics, Inc.’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -23.91%.

The current PE Ratio of Beta Bionics, Inc. is ―. Beta Bionics, Inc.’s PEG ratio is -0.41.

In the last 12 months, Beta Bionics, Inc. had revenue of 100.25M and earned -73.20M in profits. Earnings per share was -1.81.

In the last 12 months, operating cash flow was -55.81M and capital expenditures -5.60M, giving a free cash flow of -61.41M billion.

Beta Bionics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Beta Bionics, Inc. upcoming earnings date is Nov 3, 2026, After Close (Confirmed).

Beta Bionics, Inc. as a current ratio of 8.66, with Debt / Equity ratio of 2.54%

In the past 12 months, Beta Bionics, Inc. has paid 0.00 in taxes.

Beta Bionics, Inc. EV to EBITDA ratio is -17.22, with an EV/FCF ratio of -21.53.

Beta Bionics, Inc. has $180.49M in cash and marketable securities with $6.51M in debt, giving a net cash position of $173.98M billion.

Gross margin is 58.31%, with operating margin of -71.50%, and net profit margin of -73.02%.

The average price target for Beta Bionics, Inc. is $23.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy